ArticleEuropean journal of medical research2025
Systemic therapy followed by liver resection improved prognosis of hepatocellular carcinoma associated with macrovascular invasion.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThere is no standard treatment for hepatocellular carcinoma (HCC) with macrovascular invasion (MaVI). This study aimed to evaluate the effectiveness of liver resection (LR) and the timing of systemic therapy in HCC with MaVI.
methodsThe SEER database included 106,613 HCC patients, 1,892 of whom had MaVI. Patients were divided into the LR group (n = 126) and Non-LR group (n = 1,766). The LR group was further split into those receiving preoperative systemic treatment (pre-AST, n = 32) and postoperative systemic treatment (post-AST, n = 37). Overall survival (OS) was compared using Kaplan-Meier survival curves. Cox regression analysis identified independent risk factors, and propensity score matching (PSM) was used to reduce selection bias.
resultsLiver resection was performed in 12.8% of cases, including 9.4% of stage III and 2.2% of stage IV patients. After PSM, the 1-, 3-, and 5-year OS rates in the LR group were 65.9%, 37.7%, and 28.6%, respectively, compared to 29.3%, 10.1%, and 5.4% in the Non-LR group (p < 0.01). Multivariate Cox analysis identified LR as an independent factor for improved OS (HR = 0.36, 95%CI = 0.25-0.50, p < 0.01). In the pre-AST and post-AST groups, the 1-, 3-, and 5-year OS rates were 81.2%, 50.0%, 40.6% and 45.9%, 21.6%, 13.5%, respectively (p = 0.01).
conclusionsLiver resection is linked to better survival outcomes for HCC patients with macrovascular invasion, especially when preoperative systemic treatment is given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.